{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:46:52Z","timestamp":1791550012098,"version":"4.3.4"},"reference-count":240,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jhep.2025.06.010","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T02:32:38Z","timestamp":1750386758000},"page":"1172-1188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["The history and future of bile acid therapies"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5114-7799","authenticated-orcid":false,"given":"Ulrich","family":"Beuers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5224-2373","authenticated-orcid":false,"given":"Jesus M.","family":"Banales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3379-7592","authenticated-orcid":false,"given":"Saul J.","family":"Karpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Keitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-7611","authenticated-orcid":false,"given":"Catherine","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-6425","authenticated-orcid":false,"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.06.010_bib1","series-title":"Die historischen Grundlagen der Leberforschung. 1. Die Vorstellungen \u00fcber Anatomie, Physiologie und Pathologie in der Antike","author":"Mani","year":"1959"},{"key":"10.1016\/j.jhep.2025.06.010_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cld.1267","article-title":"A historical review of jaundice: may the golden oriole live forever","volume":"20","author":"Herta","year":"2022","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.jhep.2025.06.010_bib3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpgasthep0521","article-title":"Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis","volume":"3","author":"Beuers","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib4","series-title":"The growth of gastroenterologic knowledge during the twentieth century","first-page":"267","article-title":"Bile: a historical review of studies on its form and function","author":"Beuers","year":"1994"},{"key":"10.1016\/j.jhep.2025.06.010_bib5","series-title":"Die historischen Grundlagen der Leberforschung. II. Die Geschichte der Leberforschug von Galen bis Claude Bernard","author":"Mani","year":"1967"},{"key":"10.1016\/j.jhep.2025.06.010_bib6","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0022-2275(20)35109-9","article-title":"Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores","volume":"34","author":"Hagey","year":"1993","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhep.2025.06.010_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2012.02.014","article-title":"Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health","volume":"57","author":"Dilger","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib8","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(87)91610-2","article-title":"Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?","volume":"1","author":"Poupon","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.06.010_bib9","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0016-5085(89)91698-3","article-title":"Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial","volume":"97","author":"Leuschner","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0140-6736(87)91812-5","article-title":"Treatment of primary biliary cirrhosis and cholestatic disorders with ursodeoxycholic acid","volume":"2","author":"Leuschner","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.06.010_bib11","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.010_bib12","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib13","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib14","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib17","first-page":"736","article-title":"Guidelines on the diagnosis and management of primary biliary cholangitis (2021)","volume":"11","author":"You","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.010_bib20","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.010_bib21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.010_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.010_bib23","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.06.010_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhepr.2019.05.005","article-title":"New treatments\/targets for primary biliary cholangitis","volume":"1","author":"Corpechot","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.06.010_bib25","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jhep.2020.03.043","article-title":"Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis","volume":"73","author":"Corpechot","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib27","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.1840160315","article-title":"Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial","volume":"16","author":"Beuers","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0168-8278(90)90281-U","article-title":"Ursodeoxycholic acid for primary sclerosing cholangitis","volume":"11","author":"Chazouilleres","year":"1990","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib29","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0168-8278(97)80421-7","article-title":"Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study","volume":"26","author":"Stiehl","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib30","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/gast.2001.27965","article-title":"A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis","volume":"121","author":"Mitchell","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib31","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-ursodeoxycholic acid study group","volume":"336","author":"Lindor","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.010_bib32","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib33","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib34","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1007\/s00535-022-01914-3","article-title":"Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis","volume":"57","author":"Arizumi","year":"2022","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.06.010_bib35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib36","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.27074","article-title":"Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis","volume":"60","author":"Wunsch","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MEG.0b013e3281108068","article-title":"The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid","volume":"19","author":"Rudolph","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib38","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jhep.2004.01.002","article-title":"Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy","volume":"40","author":"Brandsaeter","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib39","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2003.50156","article-title":"Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"124","author":"Pardi","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.7326\/0003-4819-134-2-200101160-00008","article-title":"Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"134","author":"Tung","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2025.06.010_bib41","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/MIB.0b013e318286fa61","article-title":"Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis","volume":"19","author":"Singh","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jhep.2025.06.010_bib42","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s10620-013-2772-0","article-title":"Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis","volume":"58","author":"Hansen","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.06.010_bib43","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"106","author":"Eaton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.06.010_bib44","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/hep.1840150409","article-title":"Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease","volume":"15","author":"Beuers","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib45","series-title":"Strategies for the treatment of hepatobiliary diseases","first-page":"43","article-title":"Hepatoprotective effect of ursodeoxycholate in experimental animals","author":"Kitani","year":"1990"},{"key":"10.1016\/j.jhep.2025.06.010_bib46","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0024-3205(82)90264-8","article-title":"Tauroursodeoxycholate prevents taurocholate induced cholestasis","volume":"30","author":"Kitani","year":"1982","journal-title":"Life Sci"},{"key":"10.1016\/j.jhep.2025.06.010_bib47","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/0006-291X(90)90800-3","article-title":"Tauroursodeoxycholic acid inhibits the cytosolic Ca++ increase in human neutrophils stimulated by formyl-methionyl-leucyl-phenylalanine","volume":"171","author":"Beuers","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2025.06.010_bib48","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/0016-5085(93)90433-D","article-title":"Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes","volume":"104","author":"Beuers","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib49","first-page":"G243","article-title":"Ursodeoxycholate mobilizes intracellular Ca2+ and activates phosphorylase a in isolated hepatocytes","volume":"264","author":"Bouscarel","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jhep.2025.06.010_bib50","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1172\/JCI116921","article-title":"Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis","volume":"92","author":"Beuers","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2025.06.010_bib51","first-page":"G293","article-title":"Hepatocellular protein kinase C activation by bile acids: implications for regulation of cholesterol 7 alpha-hydroxylase","volume":"271","author":"Stravitz","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jhep.2025.06.010_bib52","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1053\/gast.1996.v110.pm8613063","article-title":"Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes","volume":"110","author":"Beuers","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib53","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2353\/ajpath.2006.050126","article-title":"Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts","volume":"168","author":"Marzioni","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2025.06.010_bib54","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1053\/gast.1997.v113.pm9322526","article-title":"Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver","volume":"113","author":"Schliess","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib55","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/hep.25992","article-title":"alpha5 beta1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes","volume":"57","author":"Gohlke","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib56","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/gast.2001.26262","article-title":"Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats","volume":"121","author":"Kurz","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib57","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1053\/jhep.2001.24034","article-title":"Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver","volume":"33","author":"Beuers","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib58","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/labinvest.3700371","article-title":"Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver","volume":"86","author":"Dombrowski","year":"2006","journal-title":"Lab Invest"},{"issue":"Pt 2","key":"10.1016\/j.jhep.2025.06.010_bib59","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1042\/bj2910355","article-title":"Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver","volume":"291","author":"Haussinger","year":"1993","journal-title":"Biochem J"},{"key":"10.1016\/j.jhep.2025.06.010_bib60","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2003.11.003","article-title":"Trafficking of the bile salt export pump from the Golgi to the canalicular membrane is regulated by the p38 MAP kinase","volume":"126","author":"Kubitz","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib61","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/gut.2007.140871","article-title":"Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-\/PKA-dependent mechanism in rat liver","volume":"57","author":"Wimmer","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.06.010_bib62","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/hep.23810","article-title":"The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies","volume":"52","author":"Beuers","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib63","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.24691","article-title":"A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes","volume":"55","author":"Hohenester","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib64","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.28550","article-title":"Soluble adenylyl cyclase regulates bile salt-induced apoptosis in human cholangiocytes","volume":"64","author":"Chang","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib65","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib66","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0022-3565(25)24517-7","article-title":"Ursodeoxycholate inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection","volume":"272","author":"Botla","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2025.06.010_bib67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF03401914","article-title":"Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production","volume":"4","author":"Rodrigues","year":"1998","journal-title":"Mol Med"},{"key":"10.1016\/j.jhep.2025.06.010_bib68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0168-8278(98)80208-0","article-title":"Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes","volume":"28","author":"Benz","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib69","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1126\/science.adu7928","article-title":"Ena-bile-ing liver cancer growth","volume":"387","author":"Goessling","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.jhep.2025.06.010_bib70","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1126\/science.adl4100","article-title":"Bile acid synthesis impedes tumor-specific T cell responses during liver cancer","volume":"387","author":"Varanasi","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.jhep.2025.06.010_bib71","doi-asserted-by":"crossref","first-page":"17810","DOI":"10.1074\/jbc.M209898200","article-title":"Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets","volume":"278","author":"Beuers","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2025.06.010_bib72","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/0016-5085(86)90859-0","article-title":"Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents","volume":"90","author":"Yoon","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib73","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.20943","article-title":"Novel biotransformation and physiological properties of norursodeoxycholic acid in humans","volume":"42","author":"Hofmann","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib74","first-page":"540","article-title":"Hypercholeresis induced by unconjugated bile acid infusion correlates with recovery in bile of unconjugated bile acids","volume":"13","author":"Gurantz","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib75","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"130","author":"Fickert","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib76","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.22891","article-title":"Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-\/- mice","volume":"49","author":"Halilbasic","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib77","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jhep.2013.01.026","article-title":"Differential effects of norUDCA and UDCA in obstructive cholestasis in mice","volume":"58","author":"Fickert","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib78","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/hep.23911","article-title":"Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver","volume":"52","author":"Denk","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib79","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2014.11.020","article-title":"24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis","volume":"62","author":"Sombetzki","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib80","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2021.06.036","article-title":"24-Norursodeoxycholic acid reshapes immunometabolism in CD8(+) T cells and alleviates hepatic inflammation","volume":"75","author":"Zhu","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib81","article-title":"24-Norursodeoxycholic acid ameliorates experimental alcohol-related liver disease and activates hepatic PPARgamma","volume":"5","author":"Grander","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.06.010_bib82","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib83","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2468-1253(19)30184-0","article-title":"Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial","volume":"4","author":"Traussnigg","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"S1","key":"10.1016\/j.jhep.2025.06.010_bib84","article-title":"Norucholic acid for the treatment of primary sclerosing cholangitis: 96-week analysis of a pivotal phase 3 trial","volume":"82","author":"Trauner","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib85","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000371904","article-title":"Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders","volume":"33","author":"Trauner","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhep.2025.06.010_bib86","doi-asserted-by":"crossref","first-page":"16S","DOI":"10.1007\/BF01536657","article-title":"Current concepts of biliary secretion","volume":"34","author":"Hofmann","year":"1989","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.06.010_bib87","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1001\/archinte.159.22.2647","article-title":"The continuing importance of bile acids in liver and intestinal disease","volume":"159","author":"Hofmann","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jhep.2025.06.010_bib88","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(93)90380-9","article-title":"Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease","volume":"75","author":"Smit","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2025.06.010_bib89","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.149360","article-title":"Active enterohepatic cycling is not required for the choleretic actions of 24-norUrsodeoxycholic acid in mice","volume":"8","author":"Truong","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhep.2025.06.010_bib90","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1053\/j.gastro.2011.06.052","article-title":"Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-kappaB-mediated inflammatory response in mice","volume":"141","author":"Fiorotto","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2024-333297","article-title":"24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T(H)17 pathogenicity and transdifferentiation","author":"Zhu","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.06.010_bib92","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2021.03.029","article-title":"Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis","volume":"75","author":"Reich","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib93","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/j.gastro.2011.09.051","article-title":"Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury","volume":"142","author":"Moustafa","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib94","first-page":"G219","article-title":"Hypercholeresis induced by norchenodeoxycholate in biliary fistula rodent","volume":"252","author":"Palmer","year":"1987","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jhep.2025.06.010_bib95","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/hep.510260218","article-title":"Effect of side chain length on biotransformation, hepatic transport, and choleretic properties of chenodeoxycholyl homologues in the rodent: studies with dinorchenodeoxycholic acid, norchenodeoxycholic acid, and chenodeoxycholic acid","volume":"26","author":"Yeh","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib96","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17425247.2016.1178233","article-title":"Bile acids and bile acid derivatives: use in drug delivery systems and as therapeutic agents","volume":"13","author":"Faustino","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.jhep.2025.06.010_bib97","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.2174\/0929867325666180309113737","article-title":"Bile acid derivatives: from old molecules to a new potent therapeutic use: an overview","volume":"25","author":"Blanchet","year":"2018","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jhep.2025.06.010_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27020471","article-title":"Synthesis and biological investigation of bile acid-paclitaxel hybrids","volume":"27","author":"Melloni","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jhep.2025.06.010_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113479","article-title":"U12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR\/S6K1 and cyclin\/CDK complex pathways","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.06.010_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/ph15010107","article-title":"Synthesis and anti-hepatoma activities of U12 derivatives arresting G0\/G1 phase and inducing apoptosis by PI3K\/AKT\/mTOR pathway","volume":"15","author":"Yang","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jhep.2025.06.010_bib101","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.bcp.2006.12.027","article-title":"Novel bile acid derivatives (BANBs) with cytostatic activity obtained by conjugation of their side chain with nitrogenated bases","volume":"73","author":"Vallejo","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhep.2025.06.010_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.599067","article-title":"Evaluation of the anticancer activity of a bile acid-dihydroartemisinin hybrid ursodeoxycholic-dihydroartemisinin in hepatocellular carcinoma cells","volume":"11","author":"Huang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhep.2025.06.010_bib103","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3835(03)00351-3","article-title":"Apoptosis and modulation of cell cycle control by synthetic derivatives of ursodeoxycholic acid and chenodeoxycholic acid in human prostate cancer cells","volume":"199","author":"Choi","year":"2003","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhep.2025.06.010_bib104","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/j.ejmech.2010.03.016","article-title":"Synthesis of bile acid derivatives and in vitro cytotoxic activity with pro-apoptotic process on multiple myeloma (KMS-11), glioblastoma multiforme (GBM), and colonic carcinoma (HCT-116) human cell lines","volume":"45","author":"Brossard","year":"2010","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jhep.2025.06.010_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23030679","article-title":"Novel semisynthetic derivatives of bile acids as effective tyrosyl-DNA phosphodiesterase 1 inhibitors","volume":"23","author":"Salomatina","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.jhep.2025.06.010_bib106","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/10611860108997927","article-title":"Liver organotropism and biotransformation of a novel platinum-ursodeoxycholate derivative, Bamet-UD2, with enhanced antitumour activity","volume":"9","author":"Larena","year":"2001","journal-title":"J Drug Target"},{"key":"10.1016\/j.jhep.2025.06.010_bib107","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/hep.31216","article-title":"Synthetic conjugates of ursodeoxycholic acid inhibit cystogenesis in experimental models of polycystic liver disease","volume":"73","author":"Caballero-Camino","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib108","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/1061186021000001841","article-title":"Relationship between tumor cell load and sensitivity to the cytostatic effect of two novel platinum-bile acid complexes, Bamet-D3 and Bamet-UD2","volume":"10","author":"Larena","year":"2002","journal-title":"J Drug Target"},{"key":"10.1016\/j.jhep.2025.06.010_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115681","article-title":"Relevance of the organic anion transporting polypeptide 1B3 (OATP1B3) in the personalized pharmacological treatment of hepatocellular carcinoma","volume":"214","author":"Asensio","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhep.2025.06.010_bib110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2015.08.022","article-title":"Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT)","volume":"216","author":"Lozano","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.jhep.2025.06.010_bib111","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41575-022-00617-7","article-title":"Genetics, pathobiology and therapeutic opportunities of polycystic liver disease","volume":"19","author":"Olaizola","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib112","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ajpath.2013.11.027","article-title":"HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis","volume":"184","author":"Gradilone","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2025.06.010_bib113","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.06.010_bib114","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2015.05.023","article-title":"Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease","volume":"63","author":"Munoz-Garrido","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib115","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jhep.2016.05.009","article-title":"Ursodeoxycholic acid in advanced polycystic liver disease: a phase 2 multicenter randomized controlled trial","volume":"65","author":"D'Agnolo","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib116","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2025.06.010_bib117","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10713","article-title":"Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis","volume":"7","author":"Gomez-Ospina","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.06.010_bib118","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2012.08.002","article-title":"Bile acid transporters and regulatory nuclear receptors in the liver and beyond","volume":"58","author":"Halilbasic","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib119","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(03)00096-5","article-title":"Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis","volume":"38","author":"Zollner","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib120","article-title":"Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis","volume":"4","author":"Braadland","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.06.010_bib121","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","article-title":"Bile acid metabolism and signalling in liver disease","volume":"82","author":"Fuchs","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib122","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abi4354","article-title":"Farnesoid X receptor antagonizes macrophage-dependent licensing of effector T lymphocytes and progression of sclerosing cholangitis","volume":"14","author":"Shi","year":"2022","journal-title":"Sci Transl Med"},{"issue":"S1","key":"10.1016\/j.jhep.2025.06.010_bib123","first-page":"1","article-title":"A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of cilofexor in patients with non-cirrhotic primary sclerosing cholangitis (PRIMIS)","volume":"78","author":"Trauner","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib124","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib125","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib126","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/hep4.1180","article-title":"Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis","volume":"2","author":"Carbone","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.06.010_bib127","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2022.08.054","article-title":"Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls","volume":"163","author":"Murillo Perez","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib128","article-title":"COBALT: a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls","author":"Kowdley","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.06.010_bib129","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/HEP.0000000000000864","article-title":"Primary biliary cholangitis drug evaluation and regulatory approval: where do we go from here?","volume":"80","author":"Jones","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib130","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2-\/- (Abcb4-\/-) mouse cholangiopathy model by promoting biliary HCO(-)(3) output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib131","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/164_2019_227","article-title":"Obeticholic acid: an update of its pharmacological activities in liver disorders","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jhep.2025.06.010_bib132","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1053\/j.gastro.2014.08.042","article-title":"The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice","volume":"147","author":"Lieu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib133","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2025.06.010_bib134","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/liv.15767","article-title":"FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob\/ob mouse model of NASH","volume":"44","author":"Di Pasqua","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.06.010_bib135","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.06.010_bib136","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","article-title":"FXR agonists for NASH: how are they different and what difference do they make?","volume":"75","author":"Kremoser","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib137","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib138","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.cgh.2022.07.024","article-title":"Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC","volume":"21","author":"Trauner","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib139","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12876-023-02653-2","article-title":"PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis","volume":"23","author":"Trauner","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2025.06.010_bib140","article-title":"Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2(-\/-) mouse model of sclerosing cholangitis","volume":"5","author":"Fuchs","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.06.010_bib141","article-title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","volume":"4","author":"Schramm","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.06.010_bib142","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib143","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1194\/jlr.M081935","article-title":"FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver","volume":"59","author":"Papazyan","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhep.2025.06.010_bib144","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.28257","article-title":"Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice","volume":"63","author":"Zhou","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib145","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35496-z","article-title":"Suppression of hepatic bile acid synthesis by a non-tumorigenic FGF19 analogue protects mice from fibrosis and hepatocarcinogenesis","volume":"8","author":"Gadaleta","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2025.06.010_bib146","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.06.010_bib147","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib148","article-title":"Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases","volume":"3","author":"Sanyal","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.06.010_bib149","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib150","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1055\/s-0041-1731707","article-title":"Role of FXR in bile acid and metabolic homeostasis in NASH: pathogenetic concepts and therapeutic opportunities","volume":"41","author":"Radun","year":"2021","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2025.06.010_bib151","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.06.010_bib152","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib153","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0016-5085(19)33499-7","article-title":"Induced alterations in composition of bile of persons having cholelithiasis","volume":"61","author":"Thistle","year":"1971","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib154","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJM197309272891303","article-title":"Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones","volume":"289","author":"Thistle","year":"1973","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.010_bib155","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/ajcn\/30.6.993","article-title":"Desaturation of bile and cholesterol gallstone dissolution with chenodeoxycholic acid","volume":"30","author":"Hofmann","year":"1977","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jhep.2025.06.010_bib156","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/hep.1840020611","article-title":"Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: a comparative randomized study","volume":"2","author":"Roda","year":"1982","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib157","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1172\/JCI110364","article-title":"Sulfation of lithocholate as a possible modifier of chenodeoxycholic acid-induced elevations of serum transaminase in patients with gallstones","volume":"68","author":"Marks","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2025.06.010_bib158","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/hep.1840040222","article-title":"Franco-Belgian cooperative study of ursodeoxycholic acid in the medical dissolution of gallstones: a double-blind, randomized, dose-response study, and comparison with chenodeoxycholic acid","volume":"4","author":"Erlinger","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib159","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198603273141304","article-title":"Fragmentation of gallstones by extracorporeal shock waves","volume":"314","author":"Sauerbruch","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.010_bib160","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1007\/s00464-021-08980-3","article-title":"Ursodeoxycholic acid for the prevention of gall stones after laparoscopic sleeve gastrectomy: a prospective controlled study","volume":"36","author":"Salman","year":"2022","journal-title":"Surg Endosc"},{"key":"10.1016\/j.jhep.2025.06.010_bib161","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S2468-1253(21)00301-0","article-title":"Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial","volume":"6","author":"Haal","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib162","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1007\/s11695-023-06893-9","article-title":"Role of ursodeoxycholic acid in the prevention of gallstones formation in bariatric patients-a systematic review and meta-analysis of randomised trials","volume":"33","author":"Sharma","year":"2023","journal-title":"Obes Surg"},{"key":"10.1016\/j.jhep.2025.06.010_bib163","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/oby.23427","article-title":"Effect of ursodeoxycholic acid on gallstone formation after bariatric surgery: an updated meta-analysis","volume":"30","author":"Ying","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jhep.2025.06.010_bib164","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/gast.2001.23947","article-title":"MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis","volume":"120","author":"Rosmorduc","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib165","article-title":"Low-phospholipid-associated cholelithiasis syndrome: prevalence, clinical features, and comorbidities","volume":"3","author":"Dong","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.06.010_bib166","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jhep.2024.04.006","article-title":"EASL Clinical Practice Guidelines on genetic cholestatic liver diseases","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib167","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev-pathmechdis-031521-025623","article-title":"Pediatric cholestatic diseases: common and unique pathogenic mechanisms","volume":"19","author":"Sutton","year":"2024","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jhep.2025.06.010_bib168","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/hep.32437","article-title":"Cholestatic liver diseases of genetic etiology: advances and controversies","volume":"75","author":"Ibrahim","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib169","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MPG.0000000000001657","article-title":"Oral cholic acid is efficacious and well tolerated in patients with bile acid synthesis and zellweger spectrum disorders","volume":"65","author":"Heubi","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.06.010_bib170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MPG.0000000000002618","article-title":"Open-label phase 3 continuation study of cholic acid in patients with inborn errors of bile acid synthesis","volume":"70","author":"Heubi","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.06.010_bib171","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1007\/s10620-020-06722-4","article-title":"Bile acid synthesis disorders in Japan: long-term outcome and chenodeoxycholic acid treatment","volume":"66","author":"Kimura","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.06.010_bib172","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1055\/s-2007-985073","article-title":"Inborn errors of bile acid metabolism","volume":"27","author":"Heubi","year":"2007","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2025.06.010_bib173","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/liv.14553","article-title":"Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis","volume":"40","author":"Kamath","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.06.010_bib174","article-title":"IBAT inhibitors in pediatric cholestatic liver diseases: transformation on the horizon?","author":"Sutton","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib175","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s13023-018-0920-5","article-title":"Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood","volume":"13","author":"Gonzales","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jhep.2025.06.010_bib176","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cld.2022.03.002","article-title":"Alagille syndrome: current understanding of pathogenesis, and challenges in diagnosis and management","volume":"26","author":"Ayoub","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2025.06.010_bib177","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1055\/s-0041-1730951","article-title":"Alagille syndrome: a focused review on clinical features, genetics, and treatment","volume":"41","author":"Kohut","year":"2021","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2025.06.010_bib178","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep4.1244","article-title":"Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in Alagille syndrome","volume":"2","author":"Shneider","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.06.010_bib179","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study","volume":"398","author":"Gonzales","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.06.010_bib180","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S2468-1253(24)00074-8","article-title":"Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"9","author":"Ovchinsky","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib181","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/HEP.0000000000000727","article-title":"Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA","volume":"79","author":"Hansen","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib182","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1097\/HEP.0000000000000502","article-title":"Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor","volume":"78","author":"Sokol","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib183","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib184","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S2468-1253(24)00080-3","article-title":"Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Miethke","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib185","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1055\/s-0030-1253223","article-title":"The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects","volume":"30","author":"Davit-Spraul","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2025.06.010_bib186","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jhep.2020.04.036","article-title":"Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults","volume":"73","author":"Stattermayer","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib187","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/apt.16118","article-title":"Review article: liver disease in adults with variants in the cholestasis-related genes ABCB11, ABCB4 and ATP8B1","volume":"52","author":"Nayagam","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.06.010_bib188","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1111\/liv.14662","article-title":"Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma","volume":"40","author":"de Vries","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.06.010_bib189","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/gutjnl-2014-306896","article-title":"Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity","volume":"64","author":"Gordo-Gilart","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.06.010_bib190","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1665-2681(19)30771-9","article-title":"Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3","volume":"14","author":"Frider","year":"2015","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib191","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s00535-013-0833-y","article-title":"Ursodeoxycholic acid stabilizes the bile salt export pump in the apical membrane in MDCK II cells","volume":"49","author":"Kagawa","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.06.010_bib192","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1038\/s41598-020-62326-y","article-title":"Evidence for functional selectivity in TUDC- and norUDCA-induced signal transduction via alpha(5)beta(1) integrin towards choleresis","volume":"10","author":"Bonus","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2025.06.010_bib193","first-page":"421","article-title":"[Ursodeoxycholic acid treatment shortens the course of cholestasis in two patients with benign recurrent intrahepatic cholestasis]","volume":"26","author":"Nicolas","year":"2003","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib194","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s10038-020-0811-1","article-title":"New paradigms of USP53 disease: normal GGT cholestasis, BRIC, cholangiopathy, and responsiveness to rifampicin","volume":"66","author":"Alhebbi","year":"2021","journal-title":"J Hum Genet"},{"key":"10.1016\/j.jhep.2025.06.010_bib195","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jhep.2020.02.007","article-title":"Genotype correlates with the natural history of severe bile salt export pump deficiency","volume":"73","author":"van Wessel","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib196","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.744488","article-title":"Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury. A systematic review","volume":"12","author":"Robles-Diaz","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhep.2025.06.010_bib197","article-title":"Odevixibat treatment in an adult patient with advanced icteric progressive cholestatic liver disease","volume":"6","author":"Herta","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.06.010_bib198","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/hep.23849","article-title":"Raised hepatic bile acid concentrations during pregnancy in mice are associated with reduced farnesoid X receptor function","volume":"52","author":"Milona","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib199","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1210\/me.2015-1014","article-title":"Estrogen and estrogen receptor-alpha-mediated transrepression of bile salt export pump","volume":"29","author":"Chen","year":"2015","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.jhep.2025.06.010_bib200","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/hep.26055","article-title":"Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype","volume":"57","author":"Abu-Hayyeh","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib201","doi-asserted-by":"crossref","first-page":"16504","DOI":"10.1074\/jbc.M109.072140","article-title":"Inhibition of Na+-taurocholate Co-transporting polypeptide-mediated bile acid transport by cholestatic sulfated progesterone metabolites","volume":"285","author":"Abu-Hayyeh","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2025.06.010_bib202","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/1471-0528.16669","article-title":"Re-evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: case-control and cohort study","volume":"128","author":"Mitchell","year":"2021","journal-title":"BJOG"},{"key":"10.1016\/j.jhep.2025.06.010_bib203","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/13557859998173","article-title":"Intrahepatic cholestasis of pregnancy: prevalence and ethnic distribution","volume":"4","author":"Abedin","year":"1999","journal-title":"Ethn Health"},{"key":"10.1016\/j.jhep.2025.06.010_bib204","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/hep.22139","article-title":"Sex hormones and bile acids in intrahepatic cholestasis of pregnancy","volume":"47","author":"Reyes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib205","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jhep.2023.03.006","article-title":"EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy","volume":"79","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib206","article-title":"Maternal liver-related symptoms during pregnancy in primary sclerosing cholangitis","volume":"6","author":"Nayagam","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.06.010_bib207","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11041068","article-title":"Cholestatic liver disease and pregnancy: a systematic review and meta-analysis","volume":"11","author":"Ferrigno","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jhep.2025.06.010_bib208","article-title":"A new diagnosis of primary biliary cholangitis in pregnancy treated with a combination of ursodeoxycholic acid and bezafibrate","author":"Harrington","year":"2024","journal-title":"Obstet Med"},{"key":"10.1016\/j.jhep.2025.06.010_bib209","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/hep.20336","article-title":"Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates","volume":"40","author":"Glantz","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib210","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/hep.26617","article-title":"Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study","volume":"59","author":"Geenes","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib211","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0140-6736(18)31877-4","article-title":"Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses","volume":"393","author":"Ovadia","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.06.010_bib212","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/1471-0528.16119","article-title":"Pregnancy outcomes in women with primary biliary cholangitis and primary sclerosing cholangitis: a retrospective cohort study","volume":"127","author":"Cauldwell","year":"2020","journal-title":"BJOG"},{"key":"10.1016\/j.jhep.2025.06.010_bib213","first-page":"367","article-title":"Effect of taurocholic acid on fetoplacental arterial pressures in a dual perfusion placental cotyledon model: a novel approach to intrahepatic cholestasis of pregnancy","volume":"59","author":"Dolinsky","year":"2014","journal-title":"J Reprod Med"},{"key":"10.1016\/j.jhep.2025.06.010_bib214","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jhep.2020.11.038","article-title":"Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations","volume":"74","author":"Vasavan","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib215","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2468-1253(21)00074-1","article-title":"Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis","volume":"6","author":"Ovadia","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib216","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1053\/j.gastro.2012.08.004","article-title":"Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis","volume":"143","author":"Bacq","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.010_bib217","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12884-020-03481-y","volume":"21","author":"Hague","year":"2021","journal-title":"BMC Pregnancy Childbirth"},{"issue":"S1","key":"10.1016\/j.jhep.2025.06.010_bib218","first-page":"S2049","volume":"78","author":"Ovadia","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib219","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41586-020-2434-2","article-title":"Whole-genome sequencing of patients with rare diseases in a national health system","volume":"583","author":"Turro","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2025.06.010_bib220","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1002\/hep4.2051","article-title":"Clinical phenotype of adult-onset liver disease in patients with variants in ABCB4, ABCB11, and ATP8B1","volume":"6","author":"Nayagam","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.06.010_bib221","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1038\/s41467-022-29931-z","article-title":"GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements","volume":"13","author":"Dixon","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.06.010_bib222","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/hep.26444","article-title":"Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study","volume":"58","author":"Marschall","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib223","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jhep.2010.02.019","article-title":"Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis","volume":"53","author":"Corpechot","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib224","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib225","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1073\/pnas.98.4.2011","article-title":"Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis","volume":"98","author":"Wang","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2025.06.010_bib226","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1194\/jlr.M200394-JLR200","article-title":"Appearance of atypical 3 alpha,6 beta,7 beta,12 alpha-tetrahydroxy-5 beta-cholan-24-oic acid in spgp knockout mice","volume":"44","author":"Perwaiz","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhep.2025.06.010_bib227","first-page":"1489","article-title":"Severe cholestasis induced by cholic acid feeding in knockout mice of sister of P-glycoprotein","volume":"38","author":"Wang","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib228","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2016.08.017","article-title":"Metabolic preconditioning protects BSEP\/ABCB11(-\/-) mice against cholestatic liver injury","volume":"66","author":"Fuchs","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib229","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/hep4.1998","article-title":"Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2(-\/-) mouse model of sclerosing cholangitis via immunomodulatory effects","volume":"6","author":"Fuchs","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.06.010_bib230","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1194\/jlr.M088070","article-title":"Hydrophilic bile acids prevent liver damage caused by lack of biliary phospholipid in Mdr2(-\/-) mice","volume":"60","author":"Wang","year":"2019","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhep.2025.06.010_bib231","article-title":"The protective role of hydrophilic tetrahydroxylated bile acids (THBA)","volume":"1866","author":"Sheps","year":"2021","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.jhep.2025.06.010_bib232","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/hep.20784","article-title":"CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice","volume":"42","author":"Wagner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.010_bib233","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/liv.12603","article-title":"Characterization and treatment of persistent hepatocellular secretory failure","volume":"35","author":"van Dijk","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.06.010_bib234","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1111\/jgh.15629","article-title":"Efficacy and safety of rifampicin in patients with persistent hepatocellular secretory failure","volume":"36","author":"Shi","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib235","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-024-00914-3","article-title":"The changing metabolic landscape of bile acids - keys to metabolism and immune regulation","volume":"21","author":"Mohanty","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib236","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.cell.2024.02.019","article-title":"The underappreciated diversity of bile acid modifications","volume":"187","author":"Mohanty","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2025.06.010_bib237","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s41586-023-06990-w","article-title":"Bile salt hydrolase catalyses formation of amine-conjugated bile acids","volume":"626","author":"Rimal","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2025.06.010_bib238","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41586-020-2047-9","article-title":"Global chemical effects of the microbiome include new bile-acid conjugations","volume":"579","author":"Quinn","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2025.06.010_bib239","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.010_bib240","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jhep.2016.03.005","article-title":"EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones","volume":"65","year":"2016","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825022779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825022779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:18:04Z","timestamp":1766081884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825022779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":240,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0168827825022779"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.06.010","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The history and future of bile acid therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}